News

Filter

101 to 110 of 97183 results

Medical burden still heavy for Chinese

10-12-2014

Chinese medical reform fiscal measures have lined the pockets of hospitals and companies but not done…

ChinaFinancialHealthcarePharmaceutical

Medicines Australia welcomes new report on Australian pharma industry

Medicines Australia welcomes new report on Australian pharma industry

10-12-2014

A new report has found that the pharmaceutical and medical technology industries in Australia produce…

AustraliaFinancialMedicines AustraliaPharmaceuticalPharmaceuticals policy

FDA Focus: Life-threatening disease and the benefit-risk of treatment options

FDA Focus: Life-threatening disease and the benefit-risk of treatment options

10-12-2014

In the fifth of a monthly FDA-focused blog published exclusively by The Pharma Letter, Dr Nicola Davies…

ChemistryFDAPharmaceuticalRegulationUSA

Spark Thera in potential $280 million hemophilia B deal with Pfizer

Spark Thera in potential $280 million hemophilia B deal with Pfizer

10-12-2014

US gene therapy start up Spark Therapeutics has entered into a global collaboration with pharma giant…

BiotechnologyHematologyLicensingPfizerSpark TherapeuticsSPK-RPE65USA

Positive top-line Ph III results with Lilly and Incyte’s baricitinib

Positive top-line Ph III results with Lilly and Incyte’s baricitinib

09-12-2014

US pharma major Eli Lilly and partner Incyte Corp today revealed that the Phase III RA-BEACON study of…

Anti-Arthritics/RheumaticsbaricitinibBiotechnologyEli LillyIncyteResearchUSA

Zydus launches world’s first biosimilar of Humira

Zydus launches world’s first biosimilar of Humira

09-12-2014

A biosimilar of AbbVie’s blockbuster drug Humira (adalimumab) has been launched in India by generic…

AbbVieAnti-Arthritics/RheumaticsBiosimilarsHumiraIndiaMarkets & MarketingZydus Cadila

ASH 2014: Gilead announces good response rates for Zydelig in non-Hodgkin lymphoma

ASH 2014: Gilead announces good response rates for Zydelig in non-Hodgkin lymphoma

09-12-2014

US biotech major Gilead Sciences has announced long-term follow-up results from the registration studies…

Gilead SciencesOncologyPharmaceuticalResearchUSAZydelig

Bayer collaborates with DNDi on novel, oral human river blindness treatment

09-12-2014

German pharma major Bayer and the Drugs for Neglected Diseases initiative (DNDi) have signed an agreement…

Astellas PharmaBayeremodepsidePharmaceuticalResearchTropical diseases

101 to 110 of 97183 results

Back to top